🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Three Dana-Farber researchers are recipients of the 2023 Outstanding Investigator Award from National Cancer Institute: Jean Zhao, PhD; Kimberly Stegmaier, MD and William G. Kaelin, Jr., MD. Congratulations! ➡️ ms.spr.ly/6019iSuiL

#ICYMI a video of our #Pathology Grand Rounds from last week featuring William Kaelin, Jr., MD (KaelinLab) of @HarvardMed & Dana-Farber. Many thanks to Dr. Kaelin. Yale School of Medicine Yale Cancer Center Yale Pathology bit.ly/3LPHp7y

Check out the group's latest "Up-Assay"! sciencedirect.com/science/articl…

Congratulations to our fantastic @a_s_ramirez and Ben Lampson for their great work on OST and its inhibition now out in Cell !! It was a fruitful collaboration with KaelinLab and Contessa Lab. #glycotime #CRISPR #cryoEM Check it out: cell.com/cell/fulltext/…

The inaugural Carnevali lecture in Kidney Cancer with our own KaelinLab as our keynote ! Dana-Farber Lank Center for Genitourinary Oncology Dana-Farber

🚨 Excited to announce my first publication from the KaelinLab in PNAS! 🎉 Our study reveals how total loss of VHL function significantly impairs neuroblastoma cell fitness via HIF2α overactivation. This sheds light on why certain VHL mutations lead to specific tumor types.

(Re)emerging Principles for Controlling Cancer with Drugs: William Kaelin will address this topic in a Keynote Address at #SABCS24 (December 10-13). Learn more: bit.ly/4f9qHg1 KaelinLab

Another great year coming to a close! Happy Holidays to everyone!

It’s Day 2 at SABCS! Presentations by our Dana-Farber’s Breast Oncology Center faculty include olaparib for BRCA+ breast cancer, and #weightloss intervention. Don't miss the Keynote by Nobel laureate William Kaelin (KaelinLab). See our full #SABCS24 schedule: bit.ly/3CVsIOH

Study in Cell co-led by Dana-Farber’s William Kaelin, MD, and Catherine Wu, MD, suggests the immune system can mount an attack on cancer cells that, due to cancer-driving mutations, present fragments of endogenous retroviral proteins on their surface. ➡️

The latest collaboration led by the KaelinLab and #WuLab with David Braun, #SteveCarr, #DerinKeskin Eli Van Allen Dana-Farber Lank Center for Genitourinary Oncology Harvard Medical School Massachusetts Institute of Technology (MIT) DF/HCC in Cell: HIF-2, ERV, T cells, HLA, renal cell carcinoma, et al…. sciencedirect.com/science/articl…

New study just out from KaelinLab in Cancer Discovery elucidating more about the dependence of #kidneycancer tumor cells on HIF2, implicating Cyclin D1 activity in resistance mechanisms to HIF2-targeted therapy aacrjournals.org/cancerdiscover…

We report that Cyclin D1 is an important direct target of HIF2 that drives the proliferation of ccRCC. Our findings further support the notion of combining HIF2 and CDK4/6 inhibitors to enhance antitumor activities. Congrats to Nitin Shirole and the team!

We had a great time celebrating the group's many accomplishments!

Two of our wonderful technicians are off to medical school this summer! Mathew and Nora were great members of the lab, we are proud of them both!

In 2023, the FDA approved belzutifan for certain kidney cancers –– thanks to years of work led by Nobel Prize recipient William G. Kaelin Jr., MD, KaelinLab. Now, Toni Choueiri, MD, director of Dana-Farber Lank Center for Genitourinary Oncology, and team are working to expand its clinical use. bit.ly/3GNeb9D